MiMedx Group Inc (MDXG)
6.155
-0.10
(-1.68%)
USD |
NASDAQ |
Apr 30, 16:00
6.50
+0.34
(+5.61%)
After-Hours: 20:00
MiMedx Group Revenue (Quarterly): 86.83M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 86.83M |
| September 30, 2023 | 81.71M |
| June 30, 2023 | 81.26M |
| March 31, 2023 | 71.68M |
| December 31, 2022 | 74.38M |
| September 30, 2022 | 67.69M |
| June 30, 2022 | 66.88M |
| March 31, 2022 | 58.89M |
| December 31, 2021 | 50.81M |
| September 30, 2021 | 63.07M |
| June 30, 2021 | 68.16M |
| March 31, 2021 | 59.97M |
| December 31, 2020 | 68.55M |
| September 30, 2020 | 64.30M |
| June 30, 2020 | 53.65M |
| March 31, 2020 | 61.74M |
| December 31, 2019 | 76.40M |
| September 30, 2019 | 88.86M |
| June 30, 2019 | 67.44M |
| March 31, 2019 | 66.56M |
| December 31, 2018 | 92.59M |
| September 30, 2018 | 86.96M |
| June 30, 2018 | 95.42M |
| March 31, 2018 | 84.15M |
| December 31, 2017 | 87.55M |
| Date | Value |
|---|---|
| September 30, 2017 | 84.57M |
| June 30, 2017 | 76.41M |
| March 31, 2017 | 72.61M |
| December 31, 2016 | 46.57M |
| September 30, 2016 | 64.43M |
| June 30, 2016 | 57.34M |
| March 31, 2016 | 53.37M |
| December 31, 2015 | 51.84M |
| September 30, 2015 | 49.02M |
| June 30, 2015 | 45.68M |
| March 31, 2015 | 40.77M |
| December 31, 2014 | 39.57M |
| September 30, 2014 | 33.52M |
| June 30, 2014 | 25.57M |
| March 31, 2014 | 19.56M |
| December 31, 2013 | 17.99M |
| September 30, 2013 | 16.12M |
| June 30, 2013 | 13.51M |
| March 31, 2013 | 11.56M |
| December 31, 2012 | 10.51M |
| September 30, 2012 | 7.954M |
| June 30, 2012 | 4.884M |
| March 31, 2012 | 3.706M |
| December 31, 2011 | 2.636M |
| September 30, 2011 | 2.152M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
50.81M
Minimum
Dec 2021
88.86M
Maximum
Sep 2019
69.07M
Average
67.69M
Median
Sep 2022
Revenue (Quarterly) Benchmarks
| TELA Bio Inc | 17.00M |
| Amylyx Pharmaceuticals Inc | 108.45M |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.065M |
| IGC Pharma Inc | 0.204M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 62.69M |
| Total Expenses (Quarterly) | 63.41M |
| EPS Diluted (Quarterly) | 0.3845 |
| Enterprise Value | 889.97M |
| Gross Profit Margin (Quarterly) | 84.06% |
| Profit Margin (Quarterly) | 72.19% |
| Earnings Yield | 6.17% |
| Operating Earnings Yield | 4.86% |
| Normalized Earnings Yield | 6.257 |